Drug Sales Trends for DEXILANT

Annual Sales Revenues and Units Sold for DEXILANT

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
DEXILANT			2021
DEXILANT			2020
DEXILANT			2019
DEXILANT			2018
DEXILANT			2017
DEXILANT			2016
DEXILANT			2015

DEXILANT Market Analysis and Financial Projection

Market Analysis and Sales Projections for Dexilant (Dexlansoprazole)

Introduction

Dexilant, also known as dexlansoprazole, is a proton pump inhibitor (PPI) used to treat conditions such as erosive esophagitis and heartburn associated with gastroesophageal reflux disease (GERD). Here is a comprehensive market analysis and sales projections for this medication.

Market Size and Growth

The global market for dexlansoprazole is experiencing significant growth. As of 2023, the global dexlansoprazole market was valued at approximately $298 million and is projected to reach $428.1 million by 2030, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period of 2024-2030[1].

Another report indicates that the dexlansoprazole market was valued at $100 million in 2023 and is expected to grow to $147 million by 2031, with a CAGR of 6% from 2024 to 2031[3].

Regional Market Analysis

• North America: This region holds a significant share of the global market, with a CAGR of 4.2% from 2024 to 2031. The demand is driven by the increasing prevalence of GERD, an aging population, and advancements in healthcare infrastructure[4].
• Europe: The European market is expected to grow at a CAGR of 4.5% from 2024 to 2031, driven by similar factors such as rising GERD cases and an aging population[4].
• Asia Pacific: This region is growing at a substantial rate, with a CAGR of 8% from 2024 to 2031. The growth is attributed to the rising rates of GERD, an increasing senior population, and improvements in healthcare infrastructure[4].
• South America: The market in this region is expected to grow at a CAGR of 5.4% from 2024 to 2031, driven by increased awareness of GERD and its treatment options[4].
• Middle East and Africa: This region is growing at a CAGR of 5.7% from 2024 to 2031, driven by the increasing prevalence of GERD and the adoption of Western lifestyles[4].

Key Players

The main players in the dexlansoprazole market include:

• Takeda Pharmaceuticals: The original developer of Dexilant.
• Par Pharmaceutical: A subsidiary of Endo International, which has launched a generic version of Dexilant[2][5].
• TWI Pharmaceuticals: Another key player in the market[1].

Product Formulations

Dexlansoprazole is available in various formulations, including:

• Delayed-release capsules: Available in 30 mg and 60 mg strengths, these capsules provide extended-release characteristics for long-lasting symptom relief[2][5].
• Other forms: The market also includes tablets, oral suspension, and dispersible tablets, catering to different patient needs[3].

Market Drivers

Several factors are driving the growth of the dexlansoprazole market:

• Increasing Prevalence of GERD: The global rise in GERD cases is a significant driver, as more people seek effective treatments for this condition[3][4].
• Aging Population: The elderly are more prone to digestive disorders, including GERD, which increases the demand for medications like dexlansoprazole[3][4].
• Advancements in Pharmaceutical Technology: Improvements in drug formulations and delivery systems enhance patient compliance and efficacy, contributing to market growth[3].
• Growing Healthcare Infrastructure: Better access to modern medical care in developing regions is also driving the market forward[3][4].

Sales Projections

• Current Sales: As of April 30, 2023, Dexilant 30 mg sales were approximately $45 million for the preceding 12 months[2][5].
• Future Projections: The market is expected to grow significantly, with the global market size projected to reach $428.1 million by 2030 and $147 million by 2031, according to different reports[1][3].

Competitive Landscape

The launch of generic versions, such as the one by Par Pharmaceutical, is expected to increase competition in the market. However, the unique delivery system and efficacy of dexlansoprazole are likely to maintain its market position[2][5].

Important Safety Information

Dexlansoprazole, like other PPIs, comes with certain contraindications and safety considerations. Patients should be aware of these before starting treatment[2].

Conclusion

The dexlansoprazole market is poised for significant growth driven by increasing GERD prevalence, an aging population, and advancements in pharmaceutical technology. With a projected CAGR of 5.3% to 6% over the next several years, the market is expected to expand substantially.

Key Takeaways

• Global Market Size: Projected to reach $428.1 million by 2030 and $147 million by 2031.
• CAGR: 5.3% to 6% from 2024 to 2030/2031.
• Key Players: Takeda Pharmaceuticals, Par Pharmaceutical, TWI Pharmaceuticals.
• Regional Growth: North America, Europe, Asia Pacific, South America, and Middle East and Africa are all experiencing growth.
• Market Drivers: Increasing GERD cases, aging population, and advancements in pharmaceutical technology.

FAQs

Q: What is the current market size of the dexlansoprazole market? A: The global dexlansoprazole market was valued at approximately $298 million in 2023[1].

Q: What is the projected CAGR for the dexlansoprazole market from 2024 to 2030? A: The projected CAGR is 5.3% from 2024 to 2030[1].

Q: Who are the main players in the dexlansoprazole market? A: The main players include Takeda Pharmaceuticals, Par Pharmaceutical, and TWI Pharmaceuticals[1][2].

Q: What are the key drivers of the dexlansoprazole market growth? A: The key drivers include the increasing prevalence of GERD, an aging population, and advancements in pharmaceutical technology[3][4].

Q: What are the different formulations available for dexlansoprazole? A: Dexlansoprazole is available in delayed-release capsules (30 mg and 60 mg), tablets, oral suspension, and dispersible tablets[3].

Sources

1. Valuates Reports: "Global Dexlansoprazole Sustained Release Capsule - Market"[1].
2. PR Newswire: "Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant"[2].
3. Market Research Intellect: "Dexlansoprazole Market Size and Projections"[3].
4. Cognitive Market Research: "Dexlansoprazole market size will expand at a compound annual growth rate (CAGR) of 6.00% from 2024 to 2031"[4].
5. Endo International: "Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant"[5].